Spear Bio - About the company
Spear Bio is a series A company based in Boston (United States), founded in 2021 by and . It operates as a Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers. Spear Bio has raised $49M in funding from investors like CDH, Foresite Capital and Bio-Techne. The company has 83 active competitors, including 17 funded and 13 that have exited. Its top competitors include companies like Abingdon Health, Olink and US BioTek Laboratories.
Company Details
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers. It offers TNAB-sure SARS-CoV-2 neutralizing antibody test kits for detecting antibodies in small samples. It also, offer a reagent-based platform for ultrasensitive protein detection in small sample volumes, with applications in research and diagnostics.
Key Metrics
Founded Year
2021
Location
Boston, United States
Stage
Series A
Total Funding
in 4 rounds
Latest Funding Round
Investors
Ranked
4th among 83 active competitors
Similar Companies
Legal entities associated with Spear Bio
Spear Bio is associated with 1 legal entity given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Dec 31, 2020 | - | 669 | 154 |
Get your free copy of Spear Bio's company profile
Spear Bio's funding and investors
Spear Bio has raised a total funding of $49M over 4 rounds. Its first funding round was on Oct 14, 2021. Its latest funding round was a Series A round on Jul 23, 2024 for $45M. 5 investors participated in its latest round, which includes Foresite Capital, Maverick Ventures, CDH and Yonghua Capital.
Spear Bio has 7 institutional investors including CDH, Foresite Capital and Bio-Techne.
Here is the list of recent funding rounds of Spear Bio:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jul 23, 2024 | $45M | Series A | 9709828 | 5047621 | Foresite Capital, Bio-Techne, and |
Nov 13, 2023 | Undisclosed | Seed | 6334560 | 5525637 | Sequoia China Seed Fund, CDH, and |
Oct 18, 2022 | $2.39M | Seed | 2165908 | 4091981 | - |
Access funding benchmarks and valuations. Sign up today!View details of Spear Bio's funding rounds and investors
Spear Bio's founders and board of directors
The founders of Spear Bio are and . has founded 1 more company - NuProbe.
View details of Spear Bio's Founder profiles and Board Members
Spear Bio's Competitors and alternates
Top competitors of Spear Bio include Abingdon Health, Olink and US BioTek Laboratories. Here is the list of Top 10 competitors of Spear Bio, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Abingdon Health 2008, York (United Kingdom), Public | Developer of immunoassays for diagnostic purposes | $24.1M | 67/100 | |
2nd | Provider of products and services for human protein biomarker research and development | - | EQT, Vitruvian PartnersÌý&²¹³¾±è;Ìý | 64/100 | |
3rd | US BioTek Laboratories 2008, Shoreline (United States), Acquired | Provider of enzyme-linked immunosorbent assay technology services | $19.5M | 64/100 | |
4th |  2021, Boston (United States), Series A | Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers | $49M | Foresite Capital, Maverick VenturesÌý&²¹³¾±è;Ìý | 56/100 |
5th |  Eclipse Bio 2017, San Diego (United States), Series A | Developer of cell-free immunoassay | $14M | Alexandria, IGlobe PartnersÌý&²¹³¾±è;Ìý | 60/100 |
6th | Virtue Diagnostics 2019, Suzhou (China), Series B | Provider of an in vitro assay platform for diagnostic solutions | $130M | MorningsideÌý&²¹³¾±è;Ìý | 59/100 |
7th |  Accellix 2007, San Jose (United States), Series D | Developer of immunotherapy-based assay delivery platform | $35.8M | Broadoak Capital Partners, CYwP FundsÌý&²¹³¾±è;Ìý | 57/100 |
8th | Provider of personalised, cell based, autologous and anti-tumour therapy | $9.43M | , EIC FundÌý&²¹³¾±è;Ìý | 56/100 | |
9th | Orbit Discovery 2015, Oxford (United Kingdom), Series A | Developer of a drug discovery platforms by peptide display engine | $15.7M | Innovate UK, Oxford University InnovationÌý&²¹³¾±è;Ìý | 54/100 |
10th |  Correlia Biosystems 2013, Berkeley (United States), Series A | Developer of immunoassay platforms to quantify proteins for proteomics and pharmaceutical applications | $10.9M | Cota Capital, Ìý&²¹³¾±è;Ìý | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Spear Bio's competitors? Click to see the top ones
Spear Bio's Investments and acquisitions
Spear Bio has made no investments or acquisitions yet.
Reports related to Spear Bio
Here is the latest report on Spear Bio's sector:
View
News related to Spear Bio
Media has covered Spear Bio for a total of 3 events in the last 1 year.
•
•
News Medical•Jul 31, 2024•Spear Bio, Foresite Capital, Bio-Techne, Maverick Ventures and 2 others
•
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Spear Bio
When was Spear Bio founded?
Spear Bio was founded in 2021.Where is Spear Bio located?
Spear Bio is located in Boston, United States.Is Spear Bio a funded company?
Spear Bio is a funded company, its first funding round was on Oct 14, 2021.When was the latest funding round of Spear Bio?
Spear Bio's latest funding round was on Jul 23, 2024.What is the annual revenue of Spear Bio?
Annual revenue of Spear Bio is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
